Entrada Therapeutics, Inc. (TRDA)
| Market Cap | 463.32M |
| Revenue (ttm) | 25.42M |
| Net Income (ttm) | -143.75M |
| Shares Out | 36.00M |
| EPS (ttm) | -3.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,974 |
| Open | 13.03 |
| Previous Close | 12.96 |
| Day's Range | 12.60 - 13.27 |
| 52-Week Range | 4.93 - 14.49 |
| Beta | -0.15 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+63.17%) |
| Earnings Date | May 8, 2026 |
About TRDA
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was f... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TRDA stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 63.17% from the latest price.
News
Entrada Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Multiple clinical readouts are expected in 2026 for DMD and DM1, with a focus on best-in-class dystrophin production and a robust cash runway into Q3 2027. Expansion into ocular diseases and a strong Vertex partnership support pipeline growth and regulatory progress.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired ...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – – Independent Dat...
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of ye...
Entrada Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Multiple clinical milestones are expected in 2024 for DMD and DM1 programs, with Q2 data anticipated to show strong safety and double-digit dystrophin levels. The EEV platform supports rapid expansion across exons, and regulatory discussions may enable higher dosing in the U.S.
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biot...
Entrada Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Multiple clinical programs in DMD and DM1 are advancing, with key data readouts expected in 2026. Expansion into ocular diseases and a robust financial position support continued growth and pipeline diversification. Entrada's EEV platform offers strong differentiation and de-risking for future programs.
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical stud...
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J....
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient coh...
Entrada Therapeutics Transcript: H.C.Wainwright @ Home Fireside Chat
EEV technology enables efficient, flexible delivery for DMD and DM1, with clinical trials for exons 44 and 45 underway and data expected in 2026. Strong regulatory engagement, low manufacturing costs, and a major DM1 partnership with Vertex position the platform for broad impact and expansion.
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- --...
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clin...
Entrada Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
Entrada's EEV platform enables efficient intracellular delivery, showing strong preclinical and early clinical results in DMD, with robust safety and PK profiles. Clinical trials are advancing globally, focusing on both pediatric and underserved adult populations, while strategic partnerships and pipeline expansion continue to drive growth.
Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2025
Four clinical programs are advancing toward activation by end of 2025, with robust progress in DMD and DM1, strong early safety and efficacy data, and a cash runway into Q2 2027. Platform expansion and new data in ocular and gene editing are expected later this year.
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON,...
Entrada Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
The EEV platform enables efficient delivery of therapeutics for DMD and DM1, with four exon skipping candidates advancing in the clinic and a strong partnership with Vertex for DM1. The company maintains a robust pipeline, including ocular programs, and has operational runway into 2027.
Entrada Therapeutics Reports First Quarter 2025 Financial Results
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping...
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon s...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical s...
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently receive...
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON,...
Azenta Announces the Election of Dipal Doshi to its Board of Directors
BURLINGTON, Mass. , Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader i...
Entrada Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Entering 2025 with strong momentum, four phase I MAD studies in DMD and DM1 are planned, supported by robust clinical and preclinical data. The EEV platform enables broad pipeline expansion, and a cash runway into Q2 2027 supports continued growth and patient-focused development.